These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36338719)
1. Preclinical evaluation and first in human study of Al Ren Y; Liu C; Liu T; Duan X; Zhang Q; Liu J; Wang P; Guo Q; Yang X; Du P; Zhu H; Yang Z Front Oncol; 2022; 12():1030187. PubMed ID: 36338719 [TBL] [Abstract][Full Text] [Related]
2. High in-vivo stability in preclinical and first-in-human experiments with [ Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493 [TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and preclinical evaluation of an Al Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046 [TBL] [Abstract][Full Text] [Related]
6. Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, preclinical evaluation, and first-in-human study of Al Wu Y; Zhang X; Zhou H; Xu B; Tian J; Sun S; Zhang J Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2774-2785. PubMed ID: 35396969 [TBL] [Abstract][Full Text] [Related]
9. Automatic radiosynthesis and preclinical evaluation of Zhou W; Huang S; Jiang Y; Hu K; Wang L; Han Y; Wu H Amino Acids; 2021 Jun; 53(6):929-938. PubMed ID: 34014365 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
12. Biodistribution and radiation dosimetry of [ Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of a novel Sui Y; Duan X; Zhang J; Chu Y; Yang X Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571 [TBL] [Abstract][Full Text] [Related]
14. Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [ Zha Z; Choi SR; Ploessl K; Alexoff D; Zhao R; Zhu L; Kung HF Bioconjug Chem; 2021 May; 32(5):1017-1026. PubMed ID: 33872489 [TBL] [Abstract][Full Text] [Related]
15. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
16. First-in-human study of PSMA-targeting agent, [ Zhao R; Ke M; Lv J; Liu S; Liu Y; Zhang J; Xu L; Gu D; Li M; Cai C; Liu Y; Zeng G; Alexoff D; Ploessl K; Zhu L; Kung HF; Wang X Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1753-1762. PubMed ID: 38212531 [TBL] [Abstract][Full Text] [Related]
17. Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging. Li Y; Duan X; Xu H; Zhang J; Zhou H; Zhang X; Zhang J; Yang Z; Hu Z; Zhang N; Tian J; Yang X Bioorg Med Chem; 2022 Jul; 66():116810. PubMed ID: 35580538 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and preclinical evaluation of novel Robu S; Schmidt A; Eiber M; Schottelius M; Günther T; Hooshyar Yousefi B; Schwaiger M; Wester HJ EJNMMI Res; 2018 Apr; 8(1):30. PubMed ID: 29651565 [TBL] [Abstract][Full Text] [Related]
19. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629 [TBL] [Abstract][Full Text] [Related]
20. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]